Measuring adherence to therapy in airways disease

Joshua Holmes, Liam G. Heaney

Source: Breathe, 17 (2) 210037; 10.1183/20734735.0037-2021
Journal Issue: June

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Joshua Holmes, Liam G. Heaney. Measuring adherence to therapy in airways disease. Breathe, 17 (2) 210037; 10.1183/20734735.0037-2021

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The clinical impact of adherence to therapy in airways disease
Source: Breathe, 17 (2) 210039; 10.1183/20734735.0039-2021
Year: 2021



Adherence rate to inhaled therapies and factors affecting adherence in elderly with chronic obstructive lung diseases
Source: International Congress 2018 – Primary care management of respiratory conditions
Year: 2018



Predicting treatment outcomes following an exacerbation of airways disease
Source: International Congress 2019 – Airway disease-associated exacerbations
Year: 2019


Patient adherence with COPD therapy
Source: Eur Respir Rev 2005; 14: 97-101
Year: 2005



Changes in the quality of life of pulmonary TB patients depending on the severity of bronchial obstruction when using standard antituberculosis therapy and inhaled bronchodilator therapy
Source: Eur Respir J 2003; 22: Suppl. 45, 21s
Year: 2003

Improving adherence in chronic airways disease: are we doing it wrongly?
Source: Breathe, 17 (2) 210022; 10.1183/20734735.0022-2021
Year: 2021



Poor adherence to ICS treatment in patients with chronic respiratory diseases
Source: Annual Congress 2013 –Monitoring symptoms and quality of life
Year: 2013

Compliance with nebulized therapy in patients with chronic lung disease
Source: Eur Respir J 2001; 18: Suppl. 33, 59s
Year: 2001

Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma?
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019

Differences in medication adherence in chronic cbstructive pulmonary disease associated with beliefs on medications
Source: International Congress 2018 – Patient-reported outcomes and scores in COPD
Year: 2018

Assessing small airways disease
Source: Eur Respir J 2008; 32: 1410
Year: 2008


The effect of statin therapy in patients with chronic obstructive airway disease
Source: International Congress 2015 – COPD: notable points
Year: 2015


Interventions to improve the adherence to controller therapy in asthmatic children
Source: Eur Respir J 2003; 22: Suppl. 45, 313s
Year: 2003

Effects of an eHealth intervention promoting correct use of medication in patients with asthma and chronic obstructive pulmonary disease
Source: Virtual Congress 2021 – Remote monitoring of respiratory patients
Year: 2021



Predictors for adherence to COPD exacerbation action plans
Source: International Congress 2018 – Let’s interact and discuss the hot topics in pulmonary rehabilitation
Year: 2018




Improving adherence in paediatric respiratory disease
Source: Breathe 2013; 9: 268-277
Year: 2013

Treatment of airway disease
Source: International Congress 2016 – Historical landmarks in respiratory medicine: contributions from the UK
Year: 2016


Adherence to inhaled therapy and its impact on chronic obstructive pulmonary disease (COPD)
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016


Predicting physician decision to prescribe systemic corticosteroids following an exacerbation of airways disease
Source: International Congress 2019 – Clinical approach to asthma management
Year: 2019


Inhaler therapy in obstructive airways disease (OAD): prescription, compliance and technique
Source: Eur Respir J 2006; 28: Suppl. 50, 57s
Year: 2006